Payment overview · 2025
General Payments
$35.35
2 reported records · 2 companies
Healthcare provider profile · identity verified
March Ellen Gray, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GILMER, TX · NPI 1629688023
Verified facts
What the public records show
CMS Open Payments records show March Ellen Gray, FNP-C received $35.35 in general payments during 2025 across 2 reported records.
Amgen Inc. accounted for 53.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Otezla.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.04 | 53.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.31 | 46.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $35.35 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 540 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 102 |
| Alprazolam | Alprazolam | 401 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 383 | 101 |
| Gabapentin | Gabapentin | 364 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 268 | 76 |
| Metformin Hcl | Metformin Hcl | 263 | 72 |
| Losartan Potassium | Losartan Potassium | 253 | 55 |
| Furosemide | Furosemide | 233 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 58 |
| Omeprazole | Omeprazole | 210 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 48 |
| Trazodone Hcl | Trazodone Hcl | 190 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 27 |
| Simvastatin | Simvastatin | 158 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 37 |
| Meloxicam | Meloxicam | 148 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 37 |
| Carvedilol | Carvedilol | 127 | 30 |
| Famotidine | Famotidine | 114 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 114 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 31 |
| Ondansetron Odt | Ondansetron | 107 | 27 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 106 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 57 |
| Montelukast Sodium | Montelukast Sodium | 104 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 21 |
| Potassium Chloride | Potassium Chloride | 102 | 23 |
| Azithromycin | Azithromycin | 99 | 75 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 18 |
| Tramadol Hcl | Tramadol Hcl | 82 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 81 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 14 |
| Glimepiride | Glimepiride | 75 | 23 |
| Bupropion Xl | Bupropion Hcl | 73 | 12 |
| Eliquis | Apixaban | 72 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 15 |
| Lorazepam | Lorazepam | 70 | suppressed |
| Allopurinol | Allopurinol | 69 | 16 |
| Ozempic | Semaglutide | 63 | 12 |
| Sertraline Hcl | Sertraline Hcl | 63 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 24 |
| Methocarbamol | Methocarbamol | 62 | 18 |
| Atenolol | Atenolol | 60 | 12 |
| Buspirone Hcl | Buspirone Hcl | 58 | 14 |
| Jardiance | Empagliflozin | 58 | 13 |
| Azelastine Hcl | Azelastine Hcl | 57 | 21 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 11 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | 13 |
| Estradiol | Estradiol | 48 | 11 |
| Glipizide | Glipizide | 45 | suppressed |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Valsartan | Valsartan | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 32 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 31 |
| Temazepam | Temazepam | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Armour Thyroid | Thyroid,pork | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 23 |
| Cephalexin | Cephalexin | 31 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Prednisone | Prednisone | 30 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 18 |
| Belsomra | Suvorexant | 24 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Topiramate | Topiramate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Primidone | Primidone | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Etodolac Er | Etodolac | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35.35 · 2 records | Amgen Inc. | Dexcom G6 Transmitter, OTEZLA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Otezla play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error